Furthermore, we have shown that treating immunocompetent mice that have GCTs with RRX-001, a downregulator of the CD47-SIRPa checkpoint pathway, induces efflux of CD68 + macrophages and efficiently dampens tumor growth, indicating that CD47-SIRPa could be a potential therapeutic target for GCT treatment. This evidence concerns the gene CD68 and neoplasm.